Our mission is to transform the clinical management of patients with cancer by developing and delivering innovative molecular imaging technologies to address unmet clinical needs, and reliably inform diagnosis and treatment decisions.
Our team is made up of industry leaders and experts in the field of radiopharmaceutical development and commercialisation.
Blue Earth Diagnostics is backed by Syncona Limited, a leading FTSE250 healthcare company focused on investing in and building global leaders in life science.
Find out how this technique works
Find out about prostate cancer
Cellular mechanisms for amino acid transport
Our research focus
Who we are
Who we work with
See how you can join the team
Where we are going to be
BURLINGTON, Mass. and OXFORD, UK, October 17, 2018 – Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced that oral and poster presentations related to the clinical use...
Read More ›Oxford, UK – October 12, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, has won the Oxford Bio Network (OBN) award for “Best Emerging Biotech ”. ...
Read More ›Oxford, UK – October 2, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that the Transparency Committee of the French Haute Autorité de Santé...
Read More ›– The Journal of Urology Publishes Results from Blue Earth Diagnostics’ LOCATE Trial of Role of 18F Fluciclovine PET/CT Imaging in the Management of Men with Recurrent Prostate Cancer...
Read More ›